Jul 24, 2025
Dec 3, 2025
Daisy Petal™ systems installed in GMP space to enable perfusion fermentation at SIIPL, enabling faster, higher-yield protein production in a compact, user-friendly platform.
Oct 10, 2025
In the face of unpredictable global market pressures, broad product pipelines, expectations for rapid profits, and the need for low-cost protein products, a rapid shift is taking place in the biotechnology industry from large-scale, single-product facilities to agile, distributed, and flexible manufacturing strategies.
Sep 18, 2025
Collaboration advances the commercialization of a 10-valent HPV vaccine.
Sep 3, 2025
Platform to advance the large-scale production and purification of virus-like particles (VLPs) for use in cost-effective human vaccines.
Aug 27, 2025
In this Q&A, Dr. Love opens up about the challenges of modern biologics manufacturing, the real-world impact of Sunflower’s technologies, and how distributed, automated solutions are changing the game for global healthcare, food science, and beyond.
Jul 24, 2025
Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today that it has engaged Alflow Scandinavia A/S as its exclusive distributor for the Daisy Petal™ Perfusion Bioreactor System in Denmark, Norway, Sweden, and Iceland. This marks Sunflower’s first commercial partnership in Europe, representing a key step in its international growth strategy.
May 19, 2025
The system is installed in the newly commissioned BioBuilder Learning Lab space in Allston Labworks for use in training local students, educators, and incumbent workers to be a passionate part of the growing biotechnology workforce.
May 12, 2025
Customers in California, Oregon, Washington, Idaho, Montana, and British Columbia can now purchase the Daisy Petal™
Apr 2, 2025
The Pharmaceutical Technology® Group spoke with Kerry Love, co-founder and CEO of Sunflower Therapeutics at INTERPHEX 2025, to find out how automation enhances the manufacture of proteins.
Mar 25, 2025
The growing development of new biotherapeutic modalities will rely heavily on automation and progressive technologies.